Cynthia M Butitta
CIK 1222082 · Chief Operating Officer · last filed 2026-07-01
Cynthia M Butitta is a Chief Operating Officer who has filed 64 SEC Form 4 insider transactions across 6 companies since 2008. The most recent filing, for AUTL, was dated Jul 1, 2026. Across all open-market trades the lifetime net is −$25.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $623.3K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
KITE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
780 BRANNAN STREET
SAN FRANCISCO, CA 94103
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AUTL | Director | — | $1.53 | — | $0 | 1 | 2026-07-01 |
| URGN | Director | 2,000 | $34.04 | $68.1K | $0 | 9 | 2026-06-24 |
| OLMA | Director | 83,876 | $6.62 | $555.3K | $0 | 8 | 2026-06-23 |
| IPSC | Director | — | $1.42 | — | $0 | 5 | 2025-06-16 |
| Kite Pharma, Inc. (KITE) Delisted | Chief Operating Officer | 121,567 | — | — | -$25.78M | 38 | 2017-09-27 |
| MABVAX THERAPEUTICS HOLDINGS, INC. (TELK) Delisted | COO and CFO | — | — | — | $0 | 2 | 2009-11-18 |
Recent Filings
64 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-01 | AUTL | Grant (A) | — | $0 | EDGAR |
| 2026-06-24 | URGN | Grant (A) | — | $0 | EDGAR |
| 2026-06-23 | OLMA | Grant (A) | — | $0 | EDGAR |
| 2025-12-01 | URGN | Exer (M) | +2,000 | $0 | EDGAR |
| 2025-08-27 | URGN | Grant (A) | — | $0 | EDGAR |
| 2025-06-16 | IPSC | Grant (A) | — | $0 | EDGAR |
| 2025-06-13 | OLMA | Grant (A) | — | $0 | EDGAR |
| 2024-08-08 | URGN | Grant (A) | — | $0 | EDGAR |
| 2024-06-21 | IPSC | Grant (A) | — | $0 | EDGAR |
| 2024-06-18 | OLMA | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.